Quantum BioPharma's Lucid-MS Receives FDA Clearance for Phase 2 MS Trial
Quantum BioPharma's Lucid-MS gets FDA clearance for Phase 2 trial in progressive MS. First-in-class drug aims to repair myelin, offering new hope for patients.
This news matters because it brings hope to millions living with progressive multiple sclerosis, a condition with few effective treatments. If Lucid-MS proves successful, it could revolutionize MS care by not just slowing the disease but potentially repairing damage, improving quality of life for patients worldwide. It also highlights the potential of innovative biotech companies to address unmet medical needs.
